Interferon primed plasmacytoid dendritic cells

A plasma cell and cell technology, applied in the field of interferon-induced plasmacytoid dendritic cells, to achieve the effect of improving pDC survival rate and high cell yield

Pending Publication Date: 2020-03-24
AARHUS UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, methods for generating large numbers of pDCs accompanied by comparative evidence that the pDCs generated are functionally and phenotypically similar (i.e. demonstrating their true similarity) have not been disclosed in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon primed plasmacytoid dendritic cells
  • Interferon primed plasmacytoid dendritic cells
  • Interferon primed plasmacytoid dendritic cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0267] Generate Pdc

[0268] To validate the experimental approach, results from best practices were reproduced and compared directly [7-10]( figure 1 a). As baseline conditions, a previously reported pDC differentiation protocol requiring 21 h in media containing the cytokines and growth factors Flt3 ligand (Flt3-L), thrombopoietin (TPO), and interleukin 3 was implemented. days [7]. Addition of stem cell factor (SCF) and StemRegenin 1 (SR1) resulted in greater expansion of progenitor cells (240-fold ± 42 compared to 35-fold ± 26 in baseline culture; figure 1 b). Blood-derived pDCs lack expression of lineage-specific surface markers (ie, CD3, CD14, CD16, CD19, CD20, and CD56) and the conventional DC marker CD11c [1]. Therefore, to evaluate the 21-day in vitro differentiation protocol defined as lin neg CD11c neg The number of putative pDCs of the cells was enriched for differentiated pDCs by immunomagnetic negative selection, hereinafter referred to as HSPC-pDCs ( figur...

Embodiment 2

[0277] Production of APCs for therapeutic use

[0278] In addition to producing type I IFN, pDCs can also act as antigen-presenting cells (APCs). One way to use our technology is in anti-tumor immunotherapy. Hematopoietic stem and progenitor cells (HSPCs) are first extracted from a patient's blood sample. HSPCs are then cultured under specific conditions to become pDCs (HSPC-pDCs). HSPC-pDC were then primed for maturation. The primed HSPC-pDCs were then activated with the inactive virus vaccine strain FSME while loading tumor antigens on them. This will induce an antigen-presenting phenotype in HSPC-pDC. Tumor antigens can be obtained directly or indirectly from cancer cells, depending on what is known about the particular cancer type. Direct access requires the loading of specific known tumor antigens onto pDCs by using liposomal nanocarriers. Indirect loading involves cancer cell isolation and co-culture of irradiated cancer cells with FSME-activated pDCs, resulting in...

Embodiment 3

[0285] Generation of genetically modified HSPC-pDC

[0286] Although it is currently not possible to genetically manipulate pDC, advances in CRISPR / Cas9 technology have led to successful and efficient targeting of CD34 + HSPCs for gene editing. Therefore, we speculate that CD34 can be initially modified by + HSPCs were then differentiated into pDCs to successfully generate gene-edited pDCs. We employed a gene editing strategy in which chemically modified synthetic sgRNA and recombinant Cas9 protein (forming a ribonucleoprotein (RNP) complex) were delivered to CD34 by electroporation + HSPC ( Figure 18 a). The sgRNA was designed to target the open reading frame and MyD88 within the first exon of IFNAR1 (subunit of the type I IFN receptor). IFNAR1 was chosen because of its role in TLR-mediated responses, while MyD88 was included because of its established role in TLR-mediated responses. A previously published sgRNA targeting the safe harbor gene CCR5 was used as a nega...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a method is provided for producing a plasmacytoid dendritic cells (pDCs), wherein hematopoietic stem and progenitor cells (HSPCs) are provided and incubated in a first medium comprising cytokines and growth factor whereby the HSPCs are differentiated into precursor-pDCs and then adding interferons (IFNs) to the first medium to obtain a second medium whereby said precursor- pDCs are differentiated into pDCs. Furthermore, a technique is provided for producing genetically modified pDCs, by initially genetically modifying HSPCs using transfection methods, including electroporation, to deliver sgRNA and Cas9 protein Moreover, a pharmaceutical formulation and a vaccine is provided which comprises pDC or genetically modified pDCs obtained according to that method.

Description

technical field [0001] The present invention relates to methods for producing interferon-primed plasmacytoid dendritic cells, antigen-presenting cells and genetically engineered plasmacytoid dendritic cells, vaccines and medicaments comprising said plasmacytoid dendritic cells or antigen-presenting cells Preparations, and methods for treating infectious diseases and / or cancer. Background technique [0002] Plasmacytoid dendritic cells (pDCs) are critical for immune competence, yet their development and function remain elusive. pDCs are key effectors of cellular immunity, capable not only of initiating immune responses but also of inducing tolerance to exogenous and endogenous antigens (Swiecki, M. and M. Colonna, The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol, 2015.15(8): Pages 471-85). pDCs differ from conventional DCs in that their final stages of development occur in the bone marrow; their antigens are acquired by receptor-mediated endocytosis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0784A61K35/15C12N5/00
CPCC12N5/0639C12N2501/125C12N2501/145C12N2501/2303C12N2501/24C12N2501/26C12N2501/60C12N2506/11A61K39/464838A61K39/464499A61K39/4622A61K39/4615A61K35/15C12N2510/00
Inventor M·雅各布森·罗尔斯卡德A·劳斯特森
Owner AARHUS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap